

Adult high-cost drug treatment pathway for psoriasis

Disclaimer

This guideline is registered at North Central London (NCL) Joint Formulary Committee (JFC) and is intended solely for use by healthcare professionals to aid the treatment of patients within NCL. However, clinical guidelines are for guidance only, their interpretation and application remain the responsibility of the individual clinician. If in doubt, contact a senior colleague or expert. Clinicians are advised to refer to the manufacturer's current prescribing information before treating individual patients.

The authors and NCL JFC accept no liability for use of this information from this beyond its intended use. While we have tried to compile accurate information in this guideline, and to keep it updated in a timely manner, we cannot guarantee that it is fully complete and correct at all times. If you identify information within this guideline that is inaccurate, please report this to the admin.ncl-mon@nhs.net. If a patient is harmed as a consequence of following this guideline, please complete a local incident report and inform admin.ncl-mon@nhs.net.

This guideline should not be used or reproduced for commercial or marketing purposes.

NCL JFC is funded by and provides advice to Acute Trusts and Clinical Commissioning Groups in NCL.

Document control

Date	Version	Amendments
Aug 2019	V1.0	New document
Nov 2019	V1.1	Risankizumab commissioned

Document management


Groups / Individuals who have overseen the development of this guidance:	<p>Royal Free London NHS Foundation Trust Dr Sandy McBride – Consultant Dermatologist Dr Adil Sheraz – Consultant Dermatologist Aoife Tynan – Dermatology Medicine Specialities Pharmacist</p> <p>NEL Karen Davies: Deputy Director – Medicines Management Adenike Fakoya – Senior Prescribing Adviser Jane Hodges - Quality & Safety Technician</p> <p>Whittington Hospital NHS Foundation Trust Dr Ben Esdaile – Consultant Dermatologist</p> <p>University College London Hospitals NHS Foundation Trust Dr Claire Martyn-Simmons – Consultant Dermatologist</p> <p>NHS Camden CCG on behalf of NCL CCGs Nisha Patel – Prescribing Adviser</p>
Groups which were consulted and have given approval:	NCL Heads of Medicines Management NCL Joint Formulary Committee
File name:	Adult high-cost drug treatment pathway for psoriasis_191127.docx
Version number:	V1.1
Available on:	www.ncl-mon.nhs.uk
Disseminated to:	NCL Trusts and CCGs
Equality impact assessment:	Low
NCL Joint Formulary Committee Approval date:	June 2019
Review date:	June 2022

Psoriasis unresponsive/contraindicated/intolerant to standard therapy (methotrexate, ciclosporin, PUVA)

Factors to consider when choosing appropriate drug

- Different efficacy and safety profiles of each drug
- Co-morbidities and potential impact of each drug option (benefit or harm), including drug specific contra-indications
- The person's views and stated preference on administration route or frequency - discuss with decision aid
- Other relevant factors e.g. conception plans, adherence, travel

After consideration of all factors choose the most clinically suitable, cost-effective drug



Clinical considerations

- Consider Infection risk
- TB - lower risk associated with etanercept, safe to use IL17 inhibitors and apremilast
- Demyelinating disease - Do not use antiTNF
- Heart failure - Avoid anti-TNF in NYHA stage III or IV HF
- High level of clearance required - Higher PASI 90 achieved with Brodalumab, Guselkumab, Ixekizumab and Risankizumab
- Conception - Certolizumab is safe to use in all stages of pregnancy and breastfeeding
- Adherence - Risankizumab and Ustekinumab are dosed at 12 weekly interval, Brodalumab and Guselkumab 8 weekly interval

IFR required